



## **Deciphera Pharmaceuticals to Announce Fourth Quarter and Full Year 2020 Financial Results and Host Conference Call and Webcast on February 9, 2021**

February 2, 2021

WALTHAM, Mass.--(BUSINESS WIRE)--Feb. 2, 2021-- Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH) today announced that it will report its fourth quarter and full year 2020 financial results on Tuesday, February 9, 2021.

In connection with the earnings release, Deciphera's management team will host a live conference call and webcast at 4:30 PM ET on Tuesday, February 9, 2021, to discuss the Company's financial results and provide a corporate update.

The conference call may be accessed by dialing (866) 930-5479 (domestic) or (409) 216-0603 (international) and referring to conference ID 5826559. A webcast of the conference call will be available in the "Events and Presentations" page in the "Investors" section of the Company's website at <https://investors.deciphera.com/news-events/events-presentations>. The archived webcast will be available on the Company's website approximately two hours after the conference call and will be available for 30 days following the call.

### **About Deciphera Pharmaceuticals**

Deciphera is a biopharmaceutical company focused on discovering, developing and commercializing important new medicines to improve the lives of people with cancer. We are leveraging our proprietary switch-control kinase inhibitor platform and deep expertise in kinase biology to develop a broad portfolio of innovative medicines. In addition to advancing multiple product candidates from our platform in clinical studies, QINLOCK is Deciphera's FDA-approved switch-control kinase inhibitor for the treatment of fourth-line gastrointestinal stromal tumor (GIST). QINLOCK is also approved for fourth-line GIST in Canada and Australia. For more information, visit [www.deciphera.com](http://www.deciphera.com) and follow us on LinkedIn and Twitter (@Deciphera).

View source version on [businesswire.com](https://www.businesswire.com/news/home/20210202005305/en/): <https://www.businesswire.com/news/home/20210202005305/en/>

#### **Investor Relations:**

Jen Robinson  
Deciphera Pharmaceuticals, Inc  
[jrobinson@deciphera.com](mailto:jrobinson@deciphera.com)  
781-906-1112

#### **Media:**

David Rosen  
Argot Partners  
[David.Rosen@argotpartners.com](mailto:David.Rosen@argotpartners.com)  
212-600-1902

Source: Deciphera Pharmaceuticals, Inc.